The Combination of Aromatase Inhibitors and GH Treatment for Idiopathic Short Stature in Male Adolescents
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgaf271 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Yiling Cui und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Hauptthemen laut MEDLINE: Aromatase Inhibitors, Human Growth Hormone, Body Height, Growth Disorders. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Major Science and Technology Project of China.
Abstract (Originalsprache)
Objective
To evaluate the efficacy and safety in adolescent boys with idiopathic short stature (ISS) when treated with third-generation aromatase inhibitors (AIs), the combination of letrozole or anastrozole with recombinant human GH (rhGH), and compare adult height (AHt) augmentation following the treatment with rhGH combined with AIs or GnRH analog (GnRHa) in male adolescents with ISS.
Method
We collected data from adolescent boys with ISS and a bone age ≥ 13 years who received treatment at Tongji Hospital, Huazhong University of Science and Technology from May 2017 to June 2023. Patients were allocated into the combined letrozole and rhGH group, the combined anastrozole and rhGH group, and the combined GnRHa and rhGH group based on their treatment. Three groups were matched by propensity score matching. There were 32 cases in each group. Follow-up was conducted every 3 months until AHt. Adverse events were monitored throughout.
Results
The SD scores of AHt adjusted for target height in the letrozole, anastrozole, and GnRHa groups were 0.60 ± 0.28, 0.81 ± 0.34, and 0.48 ± 0.17, respectively. Compared with the letrozole and GnRHa groups, the anastrazole and rhGH combination group showed the most significant increase in AHt (P < .01). The abnormal monitoring indicators of the AIs group gradually returned to normal following the termination of treatment.
Conclusion
For adolescent males with ISS and a bone age ≥ 13 years, the combination of AI and rhGH significantly increased the AHt. Finally, our analyses showed that anastrozole exerts more significant effects with regard to augmenting AHt with fewer adverse reactions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
- Hubei Provincial Key Laboratory of Pediatric Genetic Metabolic and Endocrine Rare Diseases, Wuhan 430030, China.
ORCID-Profile: Yiling Cui, Qiting Zhang, Ling Hou, Xiaoping Luo
Förderung
- National Key Research and Development Program of China
- National Major Science and Technology Project of China
Zitieren
APA
Cui, Y., Zhang, Q., Hou, L., & Luo, X. (2025). The Combination of Aromatase Inhibitors and GH Treatment for Idiopathic Short Stature in Male Adolescents. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf271
Vancouver
Cui Y, Zhang Q, Hou L, Luo X. The Combination of Aromatase Inhibitors and GH Treatment for Idiopathic Short Stature in Male Adolescents. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf271
BibTeX
@article{Cui2025,
author = {Cui, Yiling and Zhang, Qiting and Hou, Ling and Luo, Xiaoping},
title = {The Combination of Aromatase Inhibitors and GH Treatment for Idiopathic Short Stature in Male Adolescents},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgaf271}
}
EUVIMED